Provided by Tiger Trade Technology Pte. Ltd.

Global Blood Therapeutics

68.49
0.0000
Volume:- -
Turnover:224.61M
Market Cap:4.62B
PE:-13.69
High:68.49
Open:68.49
Low:68.49
Close:68.49
52wk High:73.02
52wk Low:21.65
Shares:67.48M
Float Shares:58.58M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.0019
EPS(LYR):-4.8138
ROE:-148.56%
ROA:-25.18%
PB:39.05
PE(LYR):-14.23

Loading ...

Company Profile

Company Name:
Global Blood Therapeutics
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California.